Alnylam Pharmaceuticals
ALNY
#1123
Rank
A$30.67 B
Marketcap
A$229.02
Share price
3.42%
Change (1 day)
-66.12%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): A$28.58

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is A$28.93. In 2025 the company made an earnings per share (EPS) of A$2.57.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$28.581012.03%
2025A$2.57
2023A-$5.16-62%
2022A-$13.5729.03%
2021A-$10.51-3.36%
2020A-$10.88-8.48%
2019A-$11.897.67%
2018A-$11.0439.74%
2017A-$7.9012.94%
2016A-$7.0038.84%
2015A-$5.04-32.88%
2014A-$7.51259.44%
2013A-$2.09-31.25%
2012A-$3.04

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
A$7.67-73.50%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$2.89-90.00%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
A$68.61 137.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
A-$3.84-113.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
A-$1.07-103.69%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
A-$0.28-100.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$0.66-97.73%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
A-$4.86-116.81%๐Ÿ‡บ๐Ÿ‡ธ USA